Literature DB >> 23096248

Relationship between dietary phytoestrogens and development of urinary incontinence in midlife women.

L Elaine Waetjen1, Katherine Leung, Sybil L Crawford, Mei-Hua Huang, Ellen B Gold, Gail A Greendale.   

Abstract

OBJECTIVE: Because exogenous estrogen treatment has been associated with a higher risk of urinary incontinence, our objective was to evaluate the longitudinal relationships of dietary phytoestrogen intakes (isoflavones, coumestans, and lignans) and the development of incontinence in midlife women transitioning through menopause.
METHODS: The Study of Women's Health Across the Nation (SWAN) Phytoestrogen Study was developed within SWAN, a community-based, multisite, multiracial/ethnic, prospective cohort study. SWAN interviewers administered a food consumption assessment at baseline and on follow-up visits 5 and 9. The SWAN Phytoestrogen Study created a phytonutrient database that allowed estimation of the usual daily intakes of four isoflavones, four lignans, and coumestrol. On an annual self-administered questionnaire, participants reported on the frequency and type of incontinence. We used discrete proportional hazards models to evaluate whether the estimated daily intake of each phytoestrogen class on the visit previous to the first report of incontinence was associated with the development of monthly or more incontinence versus remaining continent.
RESULTS: We found no association or patterns of association between developing any, stress, or urge incontinence and the reported daily dietary intake of isoflavones, coumestrol, and lignans on the visit previous to the onset of incontinence.
CONCLUSIONS: The results of this longitudinal study provide important information to better understand estrogenlike substances in the continence mechanism of midlife women. Our study shows that neither high nor low dietary intakes of isoflavones, coumestrol, and lignans prevent stress or urge incontinence. Future studies should evaluate whether serum levels of phytoestrogens or their metabolites impact incontinence symptoms.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23096248      PMCID: PMC3568456          DOI: 10.1097/gme.0b013e3182703c9c

Source DB:  PubMed          Journal:  Menopause        ISSN: 1072-3714            Impact factor:   2.953


  42 in total

1.  Analysis of collagen status in premenopausal nulliparous women with genuine stress incontinence.

Authors:  D P Keane; T J Sims; P Abrams; A J Bailey
Journal:  Br J Obstet Gynaecol       Date:  1997-09

2.  Adverse events reported by postmenopausal women in controlled trials with raloxifene.

Authors:  G C Davies; W J Huster; Y Lu; L Plouffe; M Lakshmanan
Journal:  Obstet Gynecol       Date:  1999-04       Impact factor: 7.661

3.  Paraurethral connective tissue in stress-incontinent women after menopause.

Authors:  C Falconer; G Ekman-Ordeberg; B Blomgren; O Johansson; U Ulmsten; G Westergren-Thorsson; A Malmström
Journal:  Acta Obstet Gynecol Scand       Date:  1998-01       Impact factor: 3.636

4.  The sensitivity and specificity of a simple test to distinguish between urge and stress urinary incontinence.

Authors:  Jeanette S Brown; Catherine S Bradley; Leslee L Subak; Holly E Richter; Stephen R Kraus; Linda Brubaker; Feng Lin; Eric Vittinghoff; Deborah Grady
Journal:  Ann Intern Med       Date:  2006-05-16       Impact factor: 25.391

5.  The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation.

Authors:  S R Cummings; S Eckert; K A Krueger; D Grady; T J Powles; J A Cauley; L Norton; T Nickelsen; N H Bjarnason; M Morrow; M E Lippman; D Black; J E Glusman; A Costa; V C Jordan
Journal:  JAMA       Date:  1999-06-16       Impact factor: 56.272

6.  Association between menopausal transition stages and developing urinary incontinence.

Authors:  L Elaine Waetjen; Jingjing Ye; Wen-Ying Feng; Wesley O Johnson; Gail A Greendale; Carolyn M Sampselle; Barbara Sternfield; Siobàn D Harlow; Ellen B Gold
Journal:  Obstet Gynecol       Date:  2009-11       Impact factor: 7.661

7.  Is equol the key to the efficacy of soy foods?

Authors:  Johanna W Lampe
Journal:  Am J Clin Nutr       Date:  2009-04-08       Impact factor: 7.045

Review 8.  Oestrogen therapy for urinary incontinence in post-menopausal women.

Authors:  June D Cody; Karen Richardson; Birgit Moehrer; Andrew Hextall; Cathryn Ma Glazener
Journal:  Cochrane Database Syst Rev       Date:  2009-10-07

9.  Association of adiposity status and changes in early to mid-adulthood with incidence of Alzheimer's disease.

Authors:  May A Beydoun; April Lhotsky; Youfa Wang; Gloria Dal Forno; Yang An; E Jeffrey Metter; Luigi Ferrucci; Richard O'Brien; Alan B Zonderman
Journal:  Am J Epidemiol       Date:  2008-10-03       Impact factor: 4.897

10.  Factors associated with worsening and improving urinary incontinence across the menopausal transition.

Authors:  L Elaine Waetjen; Wen-Ying Feng; Jingjing Ye; Wesley O Johnson; Gail A Greendale; Carolyn M Sampselle; Barbara Sternfield; Siobán D Harlow; Ellen B Gold
Journal:  Obstet Gynecol       Date:  2008-03       Impact factor: 7.661

View more
  5 in total

Review 1.  A Review of Phytoestrogens and Their Association With Pelvic Floor Conditions.

Authors:  Olivia Cardenas-Trowers; Isuzu Meyer; Alayne D Markland; Holly E Richter; Ilana Addis
Journal:  Female Pelvic Med Reconstr Surg       Date:  2018 May/Jun       Impact factor: 2.091

Review 2.  Lignan exposure: a worldwide perspective.

Authors:  Lucia Rizzolo-Brime; Elida M Caro-Garcia; Cynthia A Alegre-Miranda; Mireia Felez-Nobrega; Raul Zamora-Ros
Journal:  Eur J Nutr       Date:  2021-11-20       Impact factor: 5.614

3.  Prevention of pelvic floor disorders: international urogynecological association research and development committee opinion.

Authors:  Tony Bazi; Satoru Takahashi; Sharif Ismail; Kari Bø; Alejandra M Ruiz-Zapata; Jonathan Duckett; Dorothy Kammerer-Doak
Journal:  Int Urogynecol J       Date:  2016-03-12       Impact factor: 2.894

4.  Isoflavone Supplements for Menopausal Women: A Systematic Review.

Authors:  Li-Ru Chen; Nai-Yu Ko; Kuo-Hu Chen
Journal:  Nutrients       Date:  2019-11-04       Impact factor: 5.717

5.  Daidzein is the in vivo active compound of Puerariae Lobatae Radix water extract for muscarinic receptor-3 inhibition against overactive bladder.

Authors:  Yining Qiang; Lu Bai; Shuran Tian; Yi Ma; Pingxiang Xu; Mingchang Cheng; Yi Wu; Xiaorong Li; Ming Xue; Xuelin Zhou
Journal:  Front Pharmacol       Date:  2022-10-04       Impact factor: 5.988

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.